Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Arcturus Therapeutics Holdings (ARCT) Gains from Equity Investments (2019 - 2020)

Arcturus Therapeutics Holdings filings provide 2 years of Gains from Equity Investments readings, the most recent being $100000.0 for Q2 2020.

On a quarterly basis, Gains from Equity Investments changed N/A to $100000.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $551000.0, a N/A change, with the full-year FY2020 number at $263000.0, up 952.0% from a year prior.
Gains from Equity Investments hit $100000.0 in Q2 2020 for Arcturus Therapeutics Holdings, down from $163000.0 in the prior quarter.
In the past five years, Gains from Equity Investments ranged from a high of $288000.0 in Q1 2019 to a low of $100000.0 in Q2 2020.